Partial blockade of Kv2.1 Channel potentiates GLP-1's Insulinotropic effects in islets and reduces its dose required for improving glucose tolerance in type 2 diabetic male mice

Endocrinology

Volumn 156, Issue 1, 2015, Pages 114-123

  Rita, Rauza Sukma ^a   Dezaki, Katsuya ^a   Kurashina, Tomoyuki ^a   Kakei, Masafumi ^a   Yada, Toshihiko ^a,b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE FOR PHYSIOLOGICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; GUANGXITOXIN 1E; INSULIN; LIRAGLUTIDE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV2.1; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; ARTHROPOD PROTEIN; GUANGXITOXIN-1E, PLESIOPHRICTUS GUANGXIENSIS; KCNB1 PROTEIN, MOUSE; PEPTIDE; SHAB POTASSIUM CHANNEL; SPIDER VENOM; VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DEPOLARIZATION; DRUG POTENCY; DRUG POTENTIATION; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; LOW DRUG DOSE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; GENETICS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE;

ANIMALS; ARTHROPOD PROTEINS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; PEPTIDES; SHAB POTASSIUM CHANNELS; SPIDER VENOMS; VENOMS;

EID: 84919754276     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1728     Document Type: Article

References (42)

1. + channels. Role in stimulussecretion coupling. J Biol Chem. 1996;271:32241-32246
2. + channel families regulate insulin secretion. Mol Endocrinol. 2001;15:1423-1435
3. Yan L, Figueroa DJ, Austin CP, et al. Expression of voltage-gated potassium channels in human and rhesus pancreatic islets. Diabetes. 2004;53:597-607
4. + channels in pancreatic β-cells enhances glucose-dependent insulin secretion. J Biol Chem. 2002;277:44938-44945
5. + channels in pancreatic β cells: role, regulation and potential as therapeutic targets. Diabetologia. 2003;46:1046-1062
6. Herrington J, Sanchez M, Wunderler D, et al. Biophysical and pharmacological properties of the voltage-gated potassium current of human pancreatic β-cells. J Physiol. 2005;567:159-175
7. Herrington J,ZhouYP, BugianesiRM,et al. Blockers of the delayedrectifier potassium current in pancreatic β-cells enhance glucosedependent insulin secretion. Diabetes. 2006;55:1034-1042
8. Tamarina NA, Kuznetsov A, Fridlyand LE, Philipson LH. Delayedrectifier (KV2.1) regulation of pancreaticβ-cell calcium responses to glucose: Inhibitor specificity and modeling.AmJ Physiol Endocrinol Metab. 2005;289:E578-E585
9. Jacobson DA, Kuznetsov A, Lopez JP, Kash S, Ammälä CE, Philipson LH. Kv2.1 ablation alters glucose-induced islet electrical activity, enhancing insulin secretion. Cell Metab. 2007;6:229-235
10. Jensen MV, Haldeman JM, Zhang H, et al. Control of voltage-gated potassium channel Kv2.2 expression by pyruvate-isocitrate cycling regulates glucose-stimulated insulin secretion. J Biol Chem. 2013; 288:23128-23140
11. Zhang YX, Liu Y, Dong J, et al. An exploratory study of the association between KCNB1 rs1051295 and type 2 diabetes and its related traits in Chinese Han population. PLoS One. 2013;8:e56365
12. Drucker DJ. Glucagon-like peptides. Diabetes. 1998;47:159-169
13. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology. 2001;142:521-527
14. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481
15. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90
16. Shibasaki T, Takahashi H, Miki T, et al. Essential role of Epac2/ Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci USA. 2007;104:19333-19338
17. 2+ channel activity. Endocrinology. 1993;133:1685-1692
18. + currents in β-cells: A possible glucose-dependent insulinotropic mechanism. Diabetes. 2002;51:S443-S447
19. 2+ signaling in β-cells: Implication in the glycemic control in rodents. Diabetes. 2004;53:3142-3151
20. + channels by glucose metabolism in pancreaticβ-cells. FEBS Lett. 2009;583:2225-2230
21. 2+ signaling and insulin release in islet β-cells: novel signal transduction of ghrelin. Diabetes. 2007;56:2319-2327
22. Dezaki K, Sone H, Koizumi M, et al. Blockade of pancreatic isletderived ghrelin enhances insulin secretion to prevent high-fat dietinduced glucose intolerance. Diabetes. 2006;55:3486-3493
23. Rolin B, Larsen MO, Gotfredsen CF, et al. The long-Acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cells mass in diabetic mice. Am J Physiol Endocrinol Metab. 2002;283:E745-E752
24. Li XN, Herrington J, Petrov A, et al. The role of voltage-gated potassium channels Kv2.1 and Kv2.2 in the regulation of insulin and somatostatin release from pancreatic islets. J Pharmacol Exp Ther. 2013;344:407-416
25. Perry CM. Liraglutide: A review of its use in the management of type 2 diabetes mellitus. Drugs. 2011;71:2347-2373
26. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46-52
27. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on β-cells sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52:380-386
28. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagonlike peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609-613
29. Ahrén B. DPP-4 inhibition and islet function. J Diabetes Investig. 2012;3:3-10
30. Omar B, Ahrén B. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes. 2014;63:2196-2202
31. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3:153-165
32. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439
33. Damdindorj B, Dezaki K, Kurashina T, et al. Exogenous and endogenous ghrelin counteracts GLP-1 action to stimulate cAMP signaling and insulin secretion in islet β-cells. FEBS Lett. 2012;586: 2555-2562
34. Enserink JM, Christensen AE, de Rooij J, et al.Anovel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat Cell Biol. 2002;4:901-906
35. de Rooij J, Rehmann H, van Triest M, Cool RH, Wittinghofer A, Bos JL. Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs. J Biol Chem. 2000;275:20829-20836
36. Song WJ, Mondal P, Li Y, Lee SE, Hussain MA. Pancreatic β-cells response to increased metabolic demand and to pharmacologic secretagogues requires EPAC2A. Diabetes. 2013;62:2796-2807
37. Dezaki K, Damdindorj B, Sone H, et al. Ghrelin attenuates cAMPPKA signaling to evoke insulinostatic cascade in islet β-cells. Diabetes. 2011;60:2315-2324
38. Kim SJ, Widenmaier SB, Choi WS, et al. Pancreatic β-cells prosurvival effects of the incretin hormones involve post-translational modification of Kv2.1 delayed rectifier channels. Cell Death Differ. 2012;19:333-344
39. +currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. J Biol Chem. 2003;278:52446-52453
40. 2+ channel of rat pancreatic β-cells in a cAMP-dependent manner. Diabetes. 1997;46:1755-1760
41. Uchida K, Dezaki K, Damdindorj B, et al. Lack of TRPM2 impaired insulin secretion and glucose metabolisms in mice. Diabetes. 2011; 60:119-126
42. Yoshida M, Dezaki K, Uchida K, et al. Involvement of cAMP/EPAC/ TRPM2 activation in glucose- and incretin-induced insulin secretion. Diabetes. 2014;63:3394-3403.